EMA Recommends Granting a Marketing Authorisation for Vimseltinib By Ogkologos - September 5, 2025 284 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adults with symptomatic tenosynovial giant cell tumour Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Liquid Biopsies on the Horizon for Children with Solid Cancers April 11, 2023 FDA Approves Atezolizumab for BRAF V600 Mutation Positive Unresectable or Metastatic... August 3, 2020 PFS Benefit in Patients with Metastatic Breast Cancer Receiving Matched Treatments... October 11, 2022 Coping With Cancer Recurrence: My Perspective As Both a Patient and... January 24, 2023 Load more HOT NEWS Sister Is There To Comfort Her Little Brother As He Battles... NGS Is Effective in Identifying Actionable Genetic Alterations for Investigational Targeted... Extra or Missing Chromosomes May Help Cancer Cells Survive Treatment Teen Created App To Help His Non-Verbal Sister And Others Like...
